Statin use and non-melanoma skin cancer risk: a meta-analysis of randomized controlled trials and observational studies by Yang, Keming et al.
Oncotarget75411www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 43), pp: 75411-75417
Statin use and non-melanoma skin cancer risk: a meta-analysis 
of randomized controlled trials and observational studies
Keming Yang1, Andrew Marley1, Huilin Tang1, Yiqing Song1, Jean Y. Tang2 and Jiali 
Han1
1Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis, IN 46202-2872, USA
2Department of Dermatology, Stanford University School of Medicine, Stanford, CA 94063, USA
Correspondence to: Jiali Han, email: jialhan@iu.edu
Keywords: statins, non-melanoma skin cancer, meta-analysis
Received: June 26, 2017    Accepted: July 26, 2017    Published: August 08, 2017
Copyright: Yang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 
3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
Background: Existing evidence of the association between statin use and non-
melanoma skin cancer (NMSC) risk has been inconsistent. 
Objective: To maximize statistical power to synthesize prospective evidence on 
this relationship.
Materials and Methods: PubMed, EMBASE, Web of Science, Cochrane Central 
Register of Controlled Trials, and ClinicalTrial.gov were systematically searched up 
to December 11, 2016. A random-effects meta-analysis was conducted to calculate 
summary estimates.
Results: Our meta-analysis of 14 randomized controlled trials (RCTs) including 
63,157 subjects showed no significant association between statin use and NMSC 
risk (RR = 1.09, 95%CI = 0.85–1.39). However, meta-analysis of four observational 
studies including 1,528,215 participants showed significantly increased risk of 
NMSC among statin users compared to non-users (RR = 1.11, 95%CI = 1.02–1.22). 
Furthermore, ever using lipophilic statins (RR = 1.14, 95%CI = 1.04–1.24) or lower-
potency statins (RR = 1.14, 95%CI = 1.03–1.26), as well as usage of any statin longer 
than one year (RR = 1.14, 95%CI = 1.09–1.18) were significantly associated with 
increased NMSC risk based on observational studies.
Conclusions: Evidence from observational studies supported an association 
between statin use and increased NMSC risk. This finding should be interpreted 
with caution due to modest number of included studies, possible between-study 
heterogeneity and inherent limitations of observational studies. 
INTRODUCTION
Non-melanoma skin cancer (NMSC), including 
basal cell carcinoma (BCC) and squamous cell carcinoma 
(SCC) of the skin, is the most common cancer in the 
United States [1, 2]. Statins (HMG-CoA reductase 
inhibitors), potent cholesterol-lowering medications, 
have proven effective in the prevention of adverse 
cardiovascular events. Moreover, some studies also 
indicated a potential chemopreventive action of statins 
against overall cancer risk [3], as well as risks of cancers 
such as gastric [4], colorectal [5], breast [6], and prostate 
cancers [7]. However, evidence for risk of NMSC has 
been conflicting. Compared to controls, more NMSC 
cases were observed among the treatment group in some 
large randomized controlled trials (RCTs) of statins such 
as the Scandinavian Simvastatin Survival Study (4S) [8] 
and the Heart Protection Study (HPS) [9], but not others 
[10–12]. One previous meta-analysis found no significant 
association between statins and skin cancer [13]. A few 
prospective observational studies have specifically 
examined this hypothesis. Recently, Wang et al. [14] found 
that statins were associated with increased NMSC risk in 
the Women’s Health Initiative (WHI) cohort. A nested 
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case-control study using Denmark national registries data 
also identified a significant association between statin 
use and slightly increased risk of BCC but not SCC [15]. 
Therefore, to maximize statistical power to synthesize 
prospective evidence on the relationship between statin 
use and NMSC risk, we conducted this meta-analysis of all 
eligible prospective observational studies and randomized 
controlled trials.
RESULTS
Study selection and study characteristics
Among the 6,420 citations retrieved from the 
electronic databases, a total of seven reports that covered 
14 RCTs including 63,157 subjects and 1,211 NMSC 
events [8–12, 16, 17], as well as four observational studies 
including 1,528,215 participants and 55,793 NMSC cases 
[14, 15, 18, 19] met our eligibility criteria and were 
included in this meta-analysis. The mean duration of 
included RCTs varied from 2 to 5.4 years while the mean/
median follow-up time of included cohort studies varied 
from 3.5 to 10.5 years. A diagram of the study selection 
process is shown in Figure 1; basic characteristics of 
all included studies are shown in Table 1, and quality 
assessment results are shown in Supplementary Table 1.
Meta-analysis of statin use and NMSC risk
Meta-analysis of RCTs did not show a significant 
association between statin use and NMSC risk (RR = 1.09, 
95%CI = 0.85–1.39; I2 = 59.9%; P for heterogeneity = 
0.02). However, the meta-analysis of observational studies 
revealed a significant association. Statin users have a 
Figure 1: Flow chart of study selection.
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higher risk of NMSC than non-users (RR = 1.11, 95% CI 
= 1.02–1.22; I2 = 76.8%; P for heterogeneity = 0.002) (See 
Figure 2). Begg’s and Egger’s tests showed no significant 
evidence of publication bias (meta-analysis of RCTs: P for 
Begg’s test = 0.88, P for Egger’s test = 0.70; meta-analysis 
of observational studies: P for Begg’s test = 0.62, P for 
Egger’s test = 0.84).
Subgroup analysis of statin use and NMSC risk
The results of subgroup analyses are shown in 
Table 2. Between-group heterogeneity was not statistically 
significant in most subgroups (P > 0.05). None of the 
subgroup analyses detected a significant association 
based on RCTs (P > 0.05). However, subgroup analyses 
of observational studies revealed significantly increased 
risks of NMSC among ever-users of lipophilic statins (RR 
= 1.14, 95% CI = 1.04–1.24) or statins with lower potency 
(RR = 1.14, 95% CI = 1.03–1.26), compared to never-
users. Additionally, users of statins for more than one year 
had significantly higher NMSC risk than never-users (RR 
= 1.14, 95% CI = 1.09–1.18). 
DISCUSSION
Our meta-analysis of four prospective observational 
studies involving 1,528,215 participants and 55,793 
NMSC cases suggested a significant and positive 
association between statins and NMSC risk. However, 
our meta-analysis of 14 RCTs with 63,157 participants 
and 1,211 NMSC events did not observe such an 
Table 1: Characteristics of included studies in this meta-analysis
Randomized trials
Report 
year
Trial Name Study Design Study 
Location
Mean
Duration of 
exposure
Statins type (dose) Treatment
(NMSC cases/
participants)
Control
(NMSC cases
/participants)
Age## Men White
1994 4S RCT 5 
European 
countries#
5.4 years S (20–40 mg/day) 13/2221 6/2223 35–70 0.81 NR
2000 GISSI RCT Italy 2 years P (20 mg /day) 1/2138 1/2133 C: 60.0 ± 10.4, 
T: 59.7 ±  10.4 
0.86 NR
2001 AFCAPS 
/TexCAPS
RCT USA 5.2 years L (20–40 mg/day) 250/3304 243/3301 45–73 0.85 NR
2005 HPS RCT UK 5.3 years S (40 mg/day) 243/10269 202/10267 64.0 ± 8.4 0.75 NR
2006 ALERT,FLARE,LCAS,LIPS,Li
SA,NDA95 study 1–3
Pooled analysis 
of 8 RCTs
Variable 2.4 years F (20–80 mg/day) 103/3512 125/3289 C: 55.8 ± 11.0, 
T: 55.1 ±  11.3
0.72 0.96
2011 JUPITER RCT USA 2 years R (20mg/day) 15/8869 5/8864 66.1 ± 7.72 0.62 NR
2014 AURORA RCT Europe, 
America, 
Asia
2.4 years R (10mg/day) 1/1389 3/1378 64.2 ± 8.6 0.62 0.85
Observational study (cohort and nested case-control studies)
Publication 
year
First Author Study 
Design
Study Location 
(data source)
Follow-
up time
Exposure 
ascertainment
Outcome 
assessment
Statins type Sample 
size
Adjusted RR 
(any use vs. no 
use)
Age Men White
2016 Wang Cohort USA (WHI 
OS+CT)*
Mean: 
10.5 yrs
Self-report 
(medication 
containers)
Self–report S,L,P,F,A,C,R 118,357 1.21 (1.07–1.35) 50–79 0 1
2015 Arnspang Nest case-
control
Denmark 
(Nationwide 
registries)
≥ 1 year∆ Prescription 
registry
Cancer Registry S,L,P,F,A,C,R 464,288 BCC: 1.09 (1.06–
1.13); SCC: 1.01 
(0.91–1.11)
NR NR ~1
2009 Haukka Cohort-
record 
linkage
Finland
(Nationwide 
registries)
Mean: 
8.8 yrs
Prescription 
registry
Cancer Registry S,L,P,F,A,C,R 944,962 1.28 (1.16–1.41) Median: 
60 
0.5 NR
2009 Dore Cohort-
record 
linkage
USA
(VATTC trial)**
Median:
3.5 yrs
Pharmacy 
Benefits 
Management 
database
Physical 
examinations + 
biopsy 
S,L,P,F,A 608 0.92 (0.73–1.16) 90%
>60
0.98 0.99
Note: 1. Full name of trials: 4S: Scandinavian Simvastatin Survival Study; GISSI: Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto 
Miocardico(Italian group for the study of the survival of Myocardial Infarction); AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention 
Study; HPS: Heart Protection Study; ALERT: Assessment of LEscol in Renal Transplantation; FLARE: FLuvastatin Angiographic REstenosis trial; LCAS: 
Lipoprotein and Cholesterol Atherosclerosis Study; LIPS: Lescol Intervention Prevention Study; LiSA: Lescol in Severe Atherosclerosis trial; NDA95: 
new drug application studies; JUPITER: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) 
Trial; AURORA: A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events; 
2. Abbreviations of statins: F: Fluvastatin; L: Lovastatin; P: Pravastatin; S: Simvastatin; R: Rosuvastatin; A: Atorvastatin; C: Cerivastatin; 3. NR: not 
reported; # Five European countries: Denmark, Finland, Iceland, Norway, Sweden; ## Age was shown in range or mean ± standard deviation, C: control, T: 
treatment; * WHI OS+CT: Women’s Health Initiative (WHI) Observational Study (OS) and Clinical Trial (CT); ** VATTC: Veterans Affairs Topical Tretinoin 
Chemoprevention Trial; ∆: Incident NMSC during 2005–2009; Prescription: 1995 to 1 year before diagnosis; ~: Approximately;
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association. This may be due to the fact that RCTs usually 
have shorter follow-up period of time than observational 
studies and an increased risk of rare events (e.g. cancers) 
may not be detected during a relatively short duration. 
Besides, cancer events are not the primary endpoints of 
the RCTs for statins. Therefore, observational studies 
Table 2: Meta-analysis and subgroup analysis of randomized trials and observational studies
RCTs Observational Studies
Subgroup 
analyses
No. of 
studies RR (95%CI)
Heterogeneity No. of 
studies RR (95%CI)
Heterogeneity
I2 P I2 P
Total 7 1.09 (0.85–1.39) 59.9% 0.02 4 1.11 (1.02–1.22) 76.8% 0.002
By Category Lipophilic 4  (s,f,l) 1.04 (0.82–1.31) 69.5% 0.02 2 (s,f,l.a) 1.14 (1.04–1.24) 36.5% 0.10
Hydrophilic 3  (r,p) 1.39 (0.35–5.55) 39.1% 0.19 2 (p) 0.96 (0.81–1.15) 0.0% 0.70
By Potency Lower 5  (f,l.s.p) 1.04 (0.83–1.30) 57.3% 0.05 2 (f,l.s.p) 1.14 (1.03–1.26) 39.0% 0.08
Higher 2  (r) 1.27 (0.15–10.46) 67.1% 0.08 2 (a) 1.05 (0.94–1.17) 0.0% 0.55
By Duration < 5 years 4 1.08 (0.43–2.71) 58.2% 0.07 3 < 1 year: 1.08 
(0.99–1.18)
39.0% 0.16
3 ≥ 1 year: 1.14 
(1.09–1.18)
30.8% 0.13
3 1–< 3 years: 1.14 
(1.04–1.25)
47.9% 0.10
3 3–< 5 years: 1.14 
(1.08–1.20)
0.0% 0.67
≥ 5 years 3 1.14 (0.94–1.37) 40.4% 0.19 3 ≥ 5 years: 1.16 
(1.04–1.29)
55.7% 0.08
Note: s: Simvastain, f: Fluvastain, l: Lovastatin, r: Rosuvastatin, p: Pravastatin, a: Atorvastatin; Comparisons were conducted 
between any use and no use of statins (or statins of different type);
Figure 2: Forest plot: meta-analysis of statin use and non-melanoma skin cancer risk.
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may have some advantage of examining a long-term 
drug-safety issue.
One previous meta-analysis evaluated statins and 
all-cancer risk, among which only four RCTs were related 
to NMSC, and their pooled results indicated a significant 
association between statins and increased NMSC risk [20]. 
Another meta-analysis conducted by Li et al. [13] found no 
significant association between statins and risk of either 
melanoma or NMSC. However, that study also included 
skin cancer cases of unspecified type in the meta-analysis 
of NMSC. To our knowledge, ours is the first meta-
analysis specifically examining the relationship between 
the risk of NMSC and statins, as well as statins of different 
potency, category, and duration of use. 
Melanoma, SCC, and BCC are three major types of 
skin cancer. The underlying mechanisms of melanoma and 
non-melanoma skin cancers (SCC and BCC) are not the 
same. In terms of melanoma, which is the most serious 
type of skin cancer, most randomized controlled trials 
and observational studies published so far showed non-
significant association between statin use and melanoma 
risk [13]. Recently, sixteen years of follow-up of the Long-
term Intervention with Pravastatin in Ischemic Disease 
(LIPID) trial also reported no excess cases of melanoma 
in the intervention group, compared to the control group 
[21]. 
We still lack substantial understanding of the 
biological mechanisms by which statins affect cancer 
risk, and whether specific properties of statins make any 
difference in this process. Some studies have indicated 
that the immunomodulatory effects of statins may be 
responsible for its potential carcinogenic actions. A statin-
induced increase in CD4+CD25+ regulatory T cells 
(Tregs) may impair the host antitumor immune response 
through suppressing the tumor specific effector T cell 
response, which may lead to an increased risk of cancer 
[22]. Notably, immunosuppression is an emerging risk 
factor for NMSC [23], and may explain the high incidence 
of NMSC in the elderly populations who are susceptible 
to immunosenescence. In addition, immunosuppressant 
therapies constitute a major risk factor of developing 
post-transplantation skin cancers among organ transplant 
recipients [24]. In kidney transplant recipients, high Tregs 
levels within the peripheral circulation were associated 
with new SCC development [25]. On the contrary, some 
research has also suggested that statins exert a protective 
action against skin cancers by inhibiting the mevalonate 
and hedgehog signaling pathways, disrupting cancer cell 
growth and inducing keratinocyte apoptosis [26]. As 
statins have also been associated with reduced risks of 
several other types of cancers [7, 20], it is possible that 
statins may play roles in affecting different cancer risks 
through various biological pathways. 
Our findings should be interpreted with caution due 
to the modest number of studies we were able to include, 
possible between-study heterogeneity, as well as the 
residual confounding inherent in observational studies. 
Due to the unavailability of original data, we could not 
conduct meta-analysis separately for BCC and SCC. We 
also could not estimate dose-response effects as available 
data were too heterogeneous to pool.
In conclusion, our meta-analysis of observational 
studies supported an association between statin use and 
increased NMSC risk. In future, ongoing post-marketing 
surveillance and long-term follow-up studies of RCTs 
could provide ongoing monitoring of new NMSC cases 
that may be related to the use of statins. More prospective 
studies with large sample sizes could be conducted to 
further evaluate the association between statins and NMSC 
risk. In addition, basic research on cholesterol metabolism 
and tumor formation is needed to explore underlying 
mechanisms. 
MATERIALS AND METHODS
This meta-analysis was conducted according to the 
Preferred Reporting Items for Systematic reviews and 
Meta-analyses (PRISMA) guidelines [27]. 
Systematic search
We conducted a comprehensive and systematical 
literature search in PubMed, EMBASE, Web of 
science, Cochrane Central Register of Controlled 
Trials (CENTRAL), and ClinicalTrials.gov registry to 
identify all prospective evidence (all from inception 
to December 11th, 2016 with no language limitation). 
References list from all relevant review articles, meta-
analysis, and the identified articles were manually 
checked. The following terms were used for literature 
search: ((hydroxymethylglutaryl coenzyme A reductase 
inhibitor) OR (hydroxymethylglutaryl-coa reductase 
inhibitors) OR (HMG-CoA reductase inhibitors) OR 
(statins) OR (atorvastatin) OR (fluvastatin) OR (lovastatin) 
OR (mevastatin) OR (pravastatin) OR (pitavastatin) OR 
(rosuvastatin) OR (simvastatin) OR (cerivastatin)) AND 
((melanoma) OR (non-melanoma) OR (nonmelanoma) 
OR (basal cell carcinoma) OR (squamous cell carcinoma) 
OR (cancer) OR (neoplasms) OR (neoplasm) OR (skin 
cancer)). 
Eligibility criteria
Both randomized controlled trials and prospective 
observational studies (cohort study and nested case-
control study) were considered. Included studies should 
meet the following criteria: (1) Published and unpublished 
RCTs of statins that reported NMSC cases as adverse 
events (length of trial ≥ 24 weeks); (2) Cohort or nested 
case-control studies that examined the association between 
statin use and NMSC incidence; (3) All study participants 
were adults aged ≥ 18 years. NMSC cases referred only to 
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SCC and BCC in this meta-analysis. Retrospective case-
control studies were excluded as they were subjected to 
various biases. Also, to minimize bias, we used safety data 
from only the original trials rather than prolonged post-
trial follow-up (if available), as the majority of all subjects 
received open-label lipid-lowering treatment during the 
latter. Studies did not provide sufficient information or 
failed to meet eligibility criteria were also excluded.
Data extraction
Two reviewers (K.Y. and A.M.) independently 
performed the study selection, data extraction, and quality 
assessment. Numbers of NMSC cases were extracted 
from randomized trials and adjusted risk ratios were 
extracted from observational studies for data synthesis. 
As two included RCTs did not report NMSC events in 
the manuscript (JUPITER and AURORA) [11, 16], the 
case numbers were extracted from the “Serious Adverse 
Events” section on the ClinicalTrials.gov registry 
website. Study characteristics including first author’s 
name, publication/report year, trial name, study design, 
study location, sample size, study length, type of statins, 
exposure and outcome assessment, as well as population 
characteristics including age, sex and race of the study 
population in each included study were also extracted. 
Quality assessment
The quality of randomized trials was evaluated 
by Cochrane Risk of Bias (RoB) Tool [28]. We used 
Cochrane RoB tool to assess potential study bias in 6 
domains, including random sequence generation (selection 
bias), allocation concealment (selection bias), blinding of 
participants and personnel (performance bias), blinding of 
outcome assessment (detection bias), incomplete outcome 
data (attrition bias), and selective reporting (reporting 
bias). The quality of included observational studies 
was assessed by Newcastle-Ottawa quality assessment 
scale (NOS) [29]. Each cohort/case-control study was 
evaluated on three broad perspectives: the selection of 
the study groups, the comparability of the groups, and the 
ascertainment of the exposure and the outcome of interest. 
Data synthesis and further analysis
We used the random-effects model (DerSimonian 
and Laird inverse variance method) to estimate summary 
relative risk (RR) with a 95% confidence interval (95% 
CI). I2 statistics were used to assess between-study 
heterogeneity. Additionally, subgroup analyses were 
separately performed for RCTs and observational studies 
to explore the source of heterogeneity, based on: (1) 
category of statins (Lipophilic: Fluvastatin, Lovastatin, 
Simvastatin, Atorvastatin; Hydrophilic: Pravastatin, 
Rosuvastatin); (2) potency of statins (Lower: Fluvastatin, 
Lovastatin, Pravastatin, Simvastatin; Higher: Atorvastatin, 
Rosuvastatin); and (3) duration of statin use (< 1 year vs. 
≥ 1 year; < 5 years vs. ≥ 5 years). Publication bias was 
examined using Begg’s and Egger’s tests. All statistical 
analyses were performed with STATA version 14.2. Two-
sided α ≤ 0.05 was the significance level. 
Abbreviations 
NMSC: non-melanoma skin cancer; BCC: basal 
cell carcinoma; SCC: squamous cell carcinoma; RCT: 
randomized controlled trial; RR: risk ratio; CI: confidence 
interval.
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